Skip to main content
SpringerLink
Log in

Angiotensin-receptor blockers: Another victory

  • Clinical Trials Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomised intervention trials. Blood Press 2001, 10:190–192.

    Article  PubMed  CAS  Google Scholar 

  2. Bosch J, Yusuf S, Pogue J, et al.: Use of ramipril in preventing stroke: double blind randomised trial. Br Med J 2002, 324:699–704.

    Article  CAS  Google Scholar 

  3. Verdecchia P, Porcellati C, Reboldi G, et al.: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001, 104:2039–2044.

    Article  PubMed  CAS  Google Scholar 

  4. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  5. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882–1885.

    Article  PubMed  CAS  Google Scholar 

  6. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  7. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728.

  8. Business Wire: Merck reports additional subgroup analyses from LIFE study with investigational use of cozaar; results suggest effect of cozaar different in black patient subpopulation in study. White House Station, NJ. April 11, 2002.

Download references

Authors
  1. Domenic A. Sica MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sica, D.A. Angiotensin-receptor blockers: Another victory. Curr Hypertens Rep 4, 321–323 (2002). https://doi.org/10.1007/s11906-996-0011-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-996-0011-1

Keywords

Search

Navigation